TGFB1 and neoplasm: Combination of TGF‐β inhibition with the bispecific glucocorticoid‐induced tumour necrosis factor receptor–related protein (GITR) ligand/anti‐PD‐L1 molecule augments the efficacy of therapy in tumours with immune‐excluded ecosystem.